Results 191 to 200 of about 82,941 (302)

Cryptocaryone Exhibits ROS/MAPK-Dependent Antiproliferative and Apoptosis-Inducing Effects on Triple-Negative Breast Cancer Cells and Proof-of-Concept Breast Cancer Mouse Model. [PDF]

Drug Dev Res
Chuang YT, Liu W, Chien TM, Farooqi AA, Chang HS, Shiau JP, Chang HW.   +6 more
europepmc   +1 more source

Age‐specific breast cancer incidence by subtype, TNM stage and screening status in Sweden 2008–2019 estimated with multiple imputation

International Journal of Cancer, Volume 159, Issue 1, Page 101-110, 1 July 2026.
What's New? Breast cancer incidence in women increases with age, but which subtypes contribute the most at different ages remains unclear. Incidence patterns of breast cancer subtypes are typically under‐reported in population‐based studies due to a high proportion of cases lacking subtype information.
Leo Gkekos, Katrín Ásta Gunnarsdóttir, Keith Humphreys, Irma Fredriksson, Anna L. V. Johansson   +4 more
wiley   +1 more source

Amphiphilic Lipid-Single-Stranded DNA Conjugate-Mediated Cell Surface Engineering for Programmable Intercellular Tethering and Immune Synapse Formation. [PDF]

Biomater Res
Kim S, Lee CE, Jangid AK, Kim K.
europepmc   +1 more source

Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition)

Cancer Innovation, Volume 5, Issue 3, June 2026.
This consensus, based on the latest evidence‐based medical data, provides guidance on the standardized application and safety management of PARP inhibitors in breast cancer treatment, aiming to serve as a reference for clinical practice. ABSTRACT Breast cancer represents a major threat to women's health in China.
Fei Ma, Binghe Xu, China Anti‐Cancer Association Committee on Clinical Research of Anticancer Drugs, National Expert Committee on Monitoring Clinical Application of Antineoplastic Drugs, Breast Cancer Expert Committee of National Cancer Quality Control Center, Expert Committee on Chemotherapy Quality Control of Beijing Cancer Treatment Quality Control and Improvement Center   +5 more
wiley   +1 more source

Feilike and Its Constituent Licochalcone B Trigger Caspase-3/GSDME-Mediated Pyroptosis in Triple-Negative Breast Cancer via Modulation of the Mutant p53-Calcium/ER Stress-ROS-MAPK Axis. [PDF]

Antioxidants (Basel)
Yang J, Zhao P, Zhou L, Song H, Feng Z, Cui H, Li Y, Qiu J, Hao X.   +8 more
europepmc   +1 more source

Real‐World Efficacy of Metronomic Chemotherapy in Advanced Breast Cancer Across Molecular Subtypes

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Objective Metronomic chemotherapy (mCHT) is widely used in the treatment of breast cancer due to its low toxicity and convenience. However, there remain real‐world studies with satisfactory samples focusing on mCHT in advanced breast cancer. Methods Enrolled patients were assigned into capecitabine‐based (X‐based) group and other mCHT group ...
Hanxing Zhou, Linmin Chen, Qianyi Lu, Huailiang Wu, Kuikui Jiang, Fei Xu, Shusen Wang   +6 more
wiley   +1 more source

Development of predictive models for the prognosis of triple-negative breast cancer using multiple transcriptomic analyses. [PDF]

PLoS One
Hwangbo S, Choi Y, Ryu JY.
europepmc   +1 more source

A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis [PDF]

, 2018
Edwards, John R., Schlosberg, Christopher   +1 more
core   +1 more source

MAP kinase activation in TNBC.

We conducted an in vitro screen to identify genes associated with resistance in human TNBC cells to two separate chemotherapeutic agents. MAPK10 and MAPK12 were among the kinases most significantly activated. Other kinases were activated during resistance to chemotherapy, including STK17A. 
openaire   +1 more source

Neoadjuvant Chemotherapy for Male Breast Cancer: A Retrospective Cohort Study

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT The survival benefit of neoadjuvant chemotherapy (Neo‐CT) among male breast carcinoma (MaBC) remains unclear, and the specific population that can benefit from Neo‐CT is also not yet defined. We utilized the data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database and employed Kaplan–Meier analysis;
Zejian Yang, Peng Ni, Yu Wang, Ruixin Wang, Bo Wang, Yu Ren, Guanqun Ge, Fan Liu, Jianjun He, Can Zhou   +9 more
wiley   +1 more source